Hims & Hers gives weak outlook but says more collaborations are coming

Hims & Hers gives weak outlook but says more collaborations are coming

Shares of Hims & Hers Health fell in extended trading on Monday after the company reported first-quarter earnings that beat analysts’ expectations but offered weaker-than-expected guidance. Here’s how the company did based on average analysts’ estimates compiled by LSEG: Earnings per share: 20 cents vs. 12 cents Revenue: $586 million vs. $538 million Revenue at … Read more

Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal

Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal. The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 … Read more

CVS tops estimates, hikes guidance as insurance business shows some improvement

CVS tops estimates, hikes guidance as insurance business shows some improvement

CVS Pharmacy logo is seen in Washington DC, United States on July 9, 2024. Jakub Porzycki | Nurphoto | Getty Images CVS Health on Thursday reported first-quarter earnings and revenue that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period.  Shares of CVS were up 7% in … Read more

GE HealthCare beats on earnings, slashes full year outlook due to tariffs

GE HealthCare beats on earnings, slashes full year outlook due to tariffs

GE HealthCare reported better-than-expected first-quarter results on Wednesday, but the company slashed its annual forecast to account for the impact of President Donald Trump’s far-reaching reciprocal tariff policy. Shares of GE HealthCare were up 3% Wednesday. Here’s how the company did: Earnings per share: $1.01 adjusted vs. 91 cents expected by LSEG. Revenue: $4.78 billion … Read more

Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall

Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall

The Pfizer logo is seen outside the pharmaceutical company’s manufacturing plant, in Newbridge, Ireland February 10, 2025.  Clodagh Kilcoyne | Reuters Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company’s sales fell, largely due to dwindling revenue for its antiviral Covid pill Paxlovid. The company previously … Read more

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

FILE PHOTO: The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company now expects 2025 … Read more

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck lowers profit outlook, partly due to 0 million expected tariff hit

Nurphoto | Nurphoto | Getty Images Merck on Thursday lowered its full-year profit guidance, citing $200 million in estimated costs for tariffs and a charge tied to a recent deal. The company now expects its 2025 adjusted earnings to come in between $8.82 and $8.97, down slightly from a previous outlook of 8.88 to $9.03 … Read more

Teladoc (TDOC) Q4 earnings 2025

Teladoc (TDOC) Q4 earnings 2025

Teladoc Health Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, Dec. 31, 2024.  Michael Nagle | Bloomberg | Getty Images Teladoc Health shares fell in extended trading on Wednesday after the company reported a wider loss than analysts expected and issued disappointing quarterly guidance. Here’s … Read more

Moderna (MRNA) Q4 earnings 2024

Moderna (MRNA) Q4 earnings 2024

Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its Covid vaccine falls.  It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline … Read more